Emerging evidence positions the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon (IFN) genes (STING) pathway as a viable target in tumour immunotherapy, given its pivotal function in facilitating T lymphocytes.4, 5. This evidence concerns the gene STING1 and neoplasm.